Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - EU Market Recap: FTSE 100 (0.10%) to 8266.84, DAX +0.61% to 18610.27, CAC40 +0.14% to 8003.98, STOXX 600 +0.36% to 520.04

Jun 03 ,2024

  • Synopsis:

    • European indices ended higher, except for UK and Denmark. Markets dialed back ECB rate cut expectations beyond June following hot Eurozone CPI print. Thursday's policy decision to focus on hint about rate path for remain of the year. At the same time, yield concerns tempered somewhat by in-line fall in US core PCE inflation, which seemed to provide further support for disinflation narrative

    • On the macro-front, final manufacturing PMIs were the key releases. Also, UK May inflation expectations headed lower, according to recent Citi/YouGov inflation tracker. Expectations for one-year ahead fell to 3.1%, the lowest level since July 2021. Fits in with economist estimates anticipating official headline inflation to continue to ease in next update on 19-Jun. Citi/YouGov poll showed long-term inflation expectations (5-10 years ahead) also down to 3.2% from 3.5%. Citi highlighted this would put it back within the 2016-2019 corridor before impact of Covid pandemic and Ukraine war. Said inflation likely to fall below target in May and to offer BoE encouragement second round effects continue to fade. Recall, stickiness in core inflation and still elevated services prices saw market pushback rate cut expectations. Market split on an August move and fully priced for November with only one rate cut seen by year-end

    • In politics, ahead of Tuesday's first head-to-head TV debate between Conservative leader Sunak and Labour leader Starmer, polls still point to a big majority for the Labour Party. A poll by Electoral Calculus, which uses MRP to predict seats across the country, showed Labour's lead in the polls would translate to 485 seats versus Conservatives on 66 seats and Liberal Democrats on 59. The prediction, which has Labour on 44.7% and the Conservatives on 23.3%, considers the likelihood of tactical voting to remove the Conservatives from power. The Independent highlighted an outcome of this magnitude would have a significant impact on a future Tory leadership contest because potential leadership contenders Mordaunt and Badenoch were among those set to lose their seats. In the afternoon, wires reported that former UKIP leader Nigel Farage became leader of Reform UK and will stand as MP for Clacton

    • On the corporate newsflow front, ATOS (ATO.FP) issued a market update, in which it revealed that it has received two revised financial restructuring proposals from EPEI and Attestor Limited and one from Onepoint; still in France, the FT wrote that Sanofi (SAN.FP) is reportedly proceeding with a dual track sale process and a potential spin-off of consumer division, which is expected to value the business at ~€20B. In the UK, GSK (GSK.LN) updated on the Zantac (ranitidine) litigation and Blackstone increased its offer for Hipgnosis Songs Fund (SONG.LN) to 105/share; in Germany, Evotec (EVT.GR) and QIAGEN (QGEN) entered a software collaboration for enhanced multi-omics data insights. Elsewhere, DSM-Firmenich (DSFIR.NA) said that it forecasts mid-term organic sales growth of 5-7% and adj EBITDA margin of 22-23%

    • Looking ahead to tomorrow's calendars, Burckhardt Compression Holding (BCHN.SW), Systemair (SYSR.SS), poLight (PLT.NO), LondonMetric Property (LMP.LN), Chemring Group (CHG.LN) and Gooch & Housego (GHH.LN) will be among few other names updating investors, whilst ALK-Abello (ALK.B.DC), ITV (ITV.LN) and Kongsberg Gruppen (KOG.NO) hold CMDs. Macro-data will include Germany May unemployment change, Spain May unemployment change, Switzerland May CPI, Eurozone Apr consumer inflation expectations and UK May retail sales monitor - BRC

  • Digest:

    • Sectors - STOXX Europe 600:

      • Outperformers: Real Estate+1.56%, Telecom +1.54%, Retail +1.20%, Travel & Leisure +1.07%, Utilities +1.01%, Technology +0.86%, Construct & Mtls +0.80%, Insurance +0.53%, Financial Svcs +0.52%, Food & Beverage +0.49%, Media +0.47%, Persnl & HHold Goods +0.42%

      • Underperformers: Oil & Gas (0.66%), Health Care (0.20%), Basic Resources (0.09%), Autos & Parts +0.12%, Chemicals +0.14%, Banks +0.30%, Ind Goods & Svcs +0.35%

    • Macro:

      • Von der Leyen needs 361 votes to keep her job. Good luck with that (Politico)

      • Tories Fail to Dent Labour Polling Lead in Early UK Campaign (BBG)

      • Reform refuse to rule out Farage standing in election (Telegraph)

      • Cut rates - then what? Five questions for the ECB (Reuters)

      • Italy's Giorgetti Is in Frame as Meloni Reset Speculation Mounts (BBG)

    • Company news:

      • Notable Gainers

        • +5.8% GDS.FP (Ramsay Générale de Santé €16.40, +0.90) -- reaches agreement with the government on funding of private hospitals

        • +5.0% ATORX.SS (Alligator Bioscience SEK1.13, +0.05) -- Phase 2 mitazalimab pancreatic cancer data published in The Lancet Oncology

        • +5.0% MRL.LN (Marlowe £5.86, +0.28) -- completes sale of certain Governance, Risk & Compliance software and services assets for an Enterprise Value of £430M

        • +5.0% WIZZ.LN (Wizz Air Holdings £24.06, +1.14) -- IATA 2024 Airline Profitability Outlook

        • +4.8% EGTX.SS (Egetis Therapeutics SEK8.47, +0.39) -- awarded promising innovative medicine designation in the UK for Emcitate (tiratricol) for treatment of MCT8 deficiency

        • +4.5% AKAST.NO (Akastor NOK14.80, +0.64) -- affiliate HMH to pursue US listing

        • +4.3% SPR.LN (Springfield Properties £0.98, +0.04) -- strategic collaboration with Barratt for Durieshill

        • +3.3% EZJ.LN (EasyJet £4.76, +0.15) -- IATA 2024 Airline Profitability Outlook

        • +3.2% TNG.FP (Transgene €1.28, +0.04) -- first patient enrolled in Phase II part of trial evaluating lead cancer vaccine TG4050 in head and neck cancer

        • +2.0% HTG.LN (Hunting £4.25, +0.09) -- second OCTG order worth $86M from Kuwait Oil Company

        • +1.8% IDIA.SW (Idorsia CHF2.64, +0.05) -- new data with daridorexant presented at SLEEP 2024

        • +0.2% SAN.FP (Sanofi €89.91, +0.19) -- proceeding with dual track sale process and potential spin-off of consumer division; expected to value business at ~€20B - FT

        • +0.2% DB1.GR (Deutsche Börse €183.25, +0.30) -- May cash markets turnover €114.19B vs year-ago €106.54B

      • Notable Decliners

        • -16.8% ATO.FP (ATOS SE €1.39, -0.28) -- receives two revised financial restructuring proposals

        • -9.4% GSK.LN (GSK Plc £16.01, -1.66) -- Zantac (ranitidine) litigation update

        • -4.0% DSFIR.NA (DSM-Firmenich €101.25, -4.25) -- sees mid-term organic sales growth of 5-7% and adj EBITDA margin of 22-23% -- CMD

        • -3.4% HCM.LN (Hutchmed £2.89, -0.10) -- updated results of Phase ІІІ FRUTIGA in Nature Medicine (

        • -2.6% SAS.SS (SAS SEK0.03, -0.00) -- IATA issues 2024 Airline Profitability Outlook

        • -0.3% BOWL.LN (Hollywood Bowl Group £3.31, -0.01) -- H1 earnings

    • EU companies reporting tomorrow:

      • DACHs: Burckhardt Compression Holding (BCHN.SW)

      • Nordics: Systemair (SYSR.SS), poLight (PLT.NO)

      • UK: LondonMetric Property (LMP.LN), Chemring Group (CHG.LN), Gooch & Housego (GHH.LN)

      • CMD/events: ALK-Abello (ALK.B.DC), ITV (ITV.LN), Kongsberg Gruppen (KOG.NO)

  • Data:

    • Economics:

      • May manufacturing PMI

        • UK 51.2 vs preliminary 51.3

        • France 46.4 vs preliminary 46.7

        • Germany 45.4 vs preliminary 45.4

        • Eurozone 47.3 vs preliminary 47.4

        • Netherlands 52.5 vs consensus 51.5, prior 51.3

        • Russia 54.4 vs consensus 540, prior 54.3

        • Sweden 54.0 vs consensus 51.5, prior revised 51.9 from 51.4

        • Spain 54.0 vs consensus 52.5, prior 52.2

        • Switzerland 46.4 vs consensus 43.5, prior 41.4

        • Italy 45.6 vs consensus 48.0, prior 47.3

        • Norway 52.3 vs consensus 52.0, prior revised 52.6 from 52.4

        • Greece 54.9 vs consensus 54.9, prior 55.2

      • Netherlands Apr Retail Sales +2.3% y/y vs consensus +4.9% and prior revised +4.3% from +4.8%

      • Austria

        • Q1 GDP (1.1%) y/y vs preliminary (1.3%); +0.1% q/q vs preliminary +0.2%

        • May Unemployment Rate 6.4% vs consensus 6.5% and prior 6.8%

    • Markets:

      • WTI Crude (Jul 24): ($2.56) or (3.33%) to $74.43

      • €-$ +0.0039 or +0.36% to 1.0887

      • £-$ +0.0051 or +0.40% to 1.2789

      • €-£ (0.0006) to 0.8513

      • S&P 500 +0.67%

      • Performance year-to-date

        • FTSE 100: +6.90%

        • DAX: +11.10%

        • CAC: +6.11%

        • MIB: +14.34%

        • Stoxx 600: +8.57%

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE